Single-use technology has a critical role in the future of manufacturing, as it can eliminate costly and time-consuming cleaning and changeover costs and deliver more productive manufacturing times. Using a shared biomanufacturing facility, a biomanufacturer can minimize its investment while mitigating the risks of demand uncertainty and maximizing time to market.
Although change may be intimidating, disruptive innovation allows manufacturers to achieve increased efficiency and quality. Several drivers affect how the appropriate facility design and unit operations for a process are selected, making it imperative to properly evaluate each option.
Recently there have been many approvals for viral vector-based therapies. Manufacturing viral vector-based therapies, such as vaccines and gene and cell therapies, is complex, but a new manufacturing solution helps solve challenges.